Trial Profile

Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium (68Ga) gozetotide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Diagnostic use
Acronyms ProsPERo

Most Recent Events

22 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
12 Jan 2017 Planned initiation date changed from 1 Sep 2016 to 1 Jun 2017.
06 Sep 2016 Study phase has been changed from phase III to phase II.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com